Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 1070806

Next Previous
X
Search
Drug Profile

GSK 1070806

Alternative Names: GSK-1070806

Latest Information Update: 12 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK
  • Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 18 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • No development reported Crohn's disease; Delayed graft function; Inflammatory bowel diseases
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Jun 2024 GlaxoSmithKline plans a phase II AtDvance trial for Atopic dermatitis (In adults, In the elderly) in USA, Argentina, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Italy, Japan, South Korea, Mexico, Panama, Poland, Spain, Thailand (NCT06447506)
  • 07 Feb 2024 GlaxoSmithKline completes a phase-I trial for Atopic dermatitis (In volunteers) in USA (IV, Infusion) (NCT05590338)
  • 15 Nov 2023 Phase-II clinical trials in Atopic dermatitis (In adults, In the elderly, Treatment-experienced) in USA, Canada (SC) (NCT05999799) (EudraCT2023-505414-15-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top